BioNTech SE (22UA.DE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 965k | -- | 1965 |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 772k | -- | 1967 |
| Mr. Jens H. Holstein | CFO & Member of Management Board | 777k | -- | 1963 |
| Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board | 791k | -- | 1973 |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | 799k | -- | 1979 |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal & Business Officer & Member of the Management Board | 881k | -- | 1975 |
| Ms. Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | 1.73M | -- | 1980 |
| Ms. Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting | -- | -- | -- |
| Mr. Zach Taylor | Senior Vice President of Corporate Development & Strategy | -- | -- | -- |
| Ms. Beate Berns | Senior Vice President of Global Human Resources | -- | -- | -- |
BioNTech SE
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6,772
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Corporate Governance
Upcoming Events
May 5, 2025 at 12:30 PM UTC
BioNTech SE Earnings Date
Recent Events
June 2, 2022 at 12:00 AM UTC
Ex-Dividend Date